Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases
NCT ID: NCT00465023
Last Updated: 2017-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2003-06-30
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Proton Beam Therapy for Unresectable Liver Metastasis
NCT04456621
Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma
NCT00857805
Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
NCT02513199
Dose Escalation Study Using Proton Beam Radiotherapy for Hepatocellular Carcinoma
NCT00662246
Hypofractionated Proton Beam Radiotherapy for Inoperable Hepatocellular Carcinoma
NCT02395523
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Since we are looking for the highest dose of proton beam radiation that can be given to people safely, not everyone who participates in this study will be receiving the same amount of radiation. Small groups of people will be enrolled and given a certain dose of radiation. If they tolerate it well, the next small group of people enrolled will receive a higher dose. This will continue until we find the highest dose that can be given without causing serious or unmanageable side effects.
* Radiation treatment to the liver will be given once a day, 5 days a week (Monday-Friday), for 3 weeks. Each treatment takes about 10-20 minutes.
* A physical examination, medical history, and blood tests will be taken once a week for 3 weeks during radiation therapy. Follow-up visits will occur every 3 months for 2 years, and every 6 months thereafter for 3 years, and then annually thereafter.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Proton Beam Radiation
Proton radiation therapy
Proton Beam Radiation
Once a day, 5 days a week (Monday-Friday) for 3 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Proton Beam Radiation
Once a day, 5 days a week (Monday-Friday) for 3 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary lesion size of 6cm or less in greatest diameter
* Single or multinodular tumors (up to 3)
* 18 years of age or older
* No evidence of extrahepatic tumor
* Karnofsky performance status of 70-100
* If patient has underlying cirrhosis, only Child's classification Group A or Group B
* Adequate renal function
* Expected survival of greater than three months
Exclusion Criteria
* Evidence of non-hepatic metastatic disease
* Local conditions or systemic illnesses which would reduce the local tolerance to radiation treatment, such as serious local injuries, active collagen vascular disease, etc.
* Prior radiation treatment to affected region
* Serious psychiatric illness which would limit compliance with treatment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Dana-Farber Cancer Institute
OTHER
Brigham and Women's Hospital
OTHER
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Theodore Sunki Hong
Attending Radiation Oncologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Theodore S. Hong, MD
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
03-084
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.